M&A Club Vancouver November Meeting
Tuesday, November 19th, 2019, from 11:30 am to 1:30 pm
Topic: Discussion about all facets of BDC Financing Solutions in conjunction with our Keynote Speaker, Betsabeh Madani.
Betsabeh Madani will be sharing an overview of Investments trends, new innovation frontiers and M&A activity in Life-Sciences and Digital Health sector across North America: where large tech and pharma fit in, which regions are developing and what some recent IPOs have focused.
Speaker: Betsabeh Madani is a strategy executive with 15 years of operating and commercialization experience and has held senior management, strategy and advisory positions across a portfolio of companies in healthcare and life-sciences (3-26,000 employees, $5M-$26B Market Cap).
Betsabeh currently covers Canada for Borealis Ventures, a New England based Venture Capital firm. Previously at Cerner, she led corporate strategy for healthcare predictive analytics and ML applications as well as population health programs where she acted as GM for Diabetes and Heart Failure programs. More recently, at EquicareHealth, she served as the Vice President of Strategy and led both market positioning and vertical growth across chronic illnesses with a focus on the Oncology care space.
Outside her work in the healthcare sector, she advises early stage start-ups across tough tech and deep sciences with applications in Clean-Tech, Agriculture and Biotechnology.
Betsabeh holds an MBA from Tuck School of Business at Dartmouth, a Master of Engineering in Mechanical Engineering from UBC, and Honors Bachelors of Science in Physics and in Biochemistry from UVic.
Borealis Ventures is a healthcare focused venture capital firm, with emphasis around life sciences platforms and digital health. Previous investments include GlycoFi(protein expression platform, acquired by Merck), Adimab (antibody discovery platform), Vets First Choice (veterinary prescription management platform, NASDAQ: CVET), Avitide (affinity purification platform), Compass Therapeutics (IO and autoimmune discovery platform), Evox Therapeutics (exosome delivery platform), Orbit Discovery (peptide discovery platform), and Teckro (clinical trial software).